The goal of the Leadership and Administration Core is to ensure that translational goals of the POCRC are met and that resources are used effectively. The Leadership Core is responsible for ongoing evaluation of scientific and translational progress of all projects. If progress is not sufficient, the Executive Committee comprised of Dr. Nicole Urban, Principal Investigator, and co-principal investigators, Drs. Mary (Nora) Disis, Charles Drescher, Beth Karlan, Steve Collins, and Martin (Mac) Cheever, will take necessary action. The Executive Committee is also responsible for ensuring that cores meet the needs of projects without redundancy or confiict, providing scientific leadership, facilitafing Inter-SPORE communication, coordinafing collaborations, integrating POCRC and CCSG activities, and allocating SPORE resources. The,Leadership Core will be responsible for coordinating SPORE activities and assuring communication between the cores, projects and committees. Committees within the Leadership Core will include representation from members ofthe Patient Advocate Group to make certain that the POCRC constanfiy works towards achieving its translational goals and meeting the needs ofthe patient. The Leadership Core will provide overall guidance for the translational activities ofthe SPORE, building on established interdisciplinary collaborations. It will promote, oversee, and evaluate active interaction between the cores and the projects. Through the advisory boards and committees, the Leadership Core will provide the following functions: 1) overall management and coordination ofthe SPORE;2) meet the scientific advisory needs of the individual research projects;3) oversee, plan, and evaluate SPORE acfivifies including inter? SPORE activities;4) promote, oversee, and evaluate interaction of cores and projects;5) encourage, select, and guide developmental projects;6) provide mentoring and career development;7) manage, distribute, and re-allocate SPORE funds and other resources as appropriate;8) oversee IRB activity;9) ensure that scientific objectives can ultimately be translated to patient care;10) initiate new activities in response to important translational research opportunities. To address the needs of the projects and the cores, experts in ovarian cancer, translational research, early detection/screening, epidemiology, genomics, immunology, statistical methods, informatics, and pathology have been identified and recruited to serve in the Leadership Core. Senior leaders with relevant expertise will interact with each other on substantive committees as well as provide mentorship to POCRC investigators who are experts in their own fields but less acquainted with other disciplines that are critical to career development in ovarian cancer translational research and the overall success ofthe POCR(Z;.

Public Health Relevance

The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase I trial results with reports from ongoing Phase III efficacy trials;2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature;and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-15
Application #
8523021
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$143,287
Indirect Cost
$42,768
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Stephan, Sirkka B; Taber, Alexandria M; Jileaeva, Ilona et al. (2015) Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33:97-101
Karlan, Beth Y; Thorpe, Jason; Watabayashi, Kate et al. (2014) Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev 23:1383-93
Cecil, Denise L; Holt, Gregory E; Park, Kyong Hwa et al. (2014) Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 74:2710-8
Palanca-Wessels, Maria Corinna; Press, Oliver W (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123:2293-301
Miller, Chris P; Thorpe, Jason D; Kortum, Amanda N et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301-6
Topp, Monique D; Hartley, Lynne; Cook, Michele et al. (2014) Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 8:656-68
Pennington, Kathryn P; Walsh, Tom; Harrell, Maria I et al. (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-75
Cheon, Dong-Joo; Orsulic, Sandra (2014) Ten-gene biomarker panel: a new hope for ovarian cancer? Biomark Med 8:523-6
Duggan, Catherine; Wang, Ching-Yun; Xiao, Liren et al. (2014) Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. Cancer Prev Res (Phila) 7:906-12
Emori, Megan M; Drapkin, Ronny (2014) The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol 12:60

Showing the most recent 10 out of 129 publications